Connection

William Creasman to Bevacizumab

Back to Details
This is a "connection" page, showing publications William Creasman has written about Bevacizumab.
William Creasman
Connection Strength
0.143
Bevacizumab
  1. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 07; 390(10103):1654-1663.
    View in: PubMed
    Score: 0.143
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.